NASDAQ
No price data available for this timeframe.
Galectin Therapeutics Inc. (GALT) has a price/fcf ratio of -11.13x as of Monday, May 25, 2026. This represents a 268.12% decrease compared to its 12-month average of -3.02x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.